Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.42 |
| ▸ | NRP1 | O14786 | 2/20 | 0.42 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.37 |
| ▸ | MASP2 | O00187 | 3/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.36 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29496505 | 0.92 | PRCP (0.42) | PRCPMEN1KMT2ADPP7NRP1 | |
| SCHEMBL30193521 | 0.90 | MEN1 (0.45) | PRCPMEN1KMT2ADPP7C3AR1 | |
| SCHEMBL31572023 | 0.90 | MEN1 (0.48) | PRCPMEN1KMT2ADPP7C3AR1 | |
| SCHEMBL29886918 | 0.90 | PRCP (0.42) | PRCPMEN1KMT2ADPP7C3AR1 | |
| SCHEMBL29947814 | 0.87 | PRCP (0.44) | PRCPMEN1KMT2ADPP7CALCRL | |
| SCHEMBL29947667 | 0.87 | EED (0.41) | PRCPMEN1KMT2ADPP7MAPK8 | |
| SCHEMBL29535027 | 0.86 | CPB2 (0.46) | MEN1KMT2ADPP7CPB2 | |
| SCHEMBL30193219 | 0.85 | MEN1 (0.42) | PRCPMEN1KMT2ADPP7C3AR1 | |
| SCHEMBL30193311 | 0.85 | MEN1 (0.42) | PRCPMEN1KMT2ADPP7C3AR1 | |
| SCHEMBL30416888 | 0.85 | MAPK8 (0.42) | PRCPMEN1KMT2ADPP7NRP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250262312-A1 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | SEAGEN INC (US) | 2025-08-21 | — | — | US | disclosed |
| US-20240366779-A1 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | SEAGEN INC (US) | 2024-11-07 | — | — | US | disclosed |
| US-12036286-B2 | Selective drug release from internalized conjugates of biologically active compounds | SEAGEN INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240207427-A1 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | SEAGEN INC (US) | 2024-06-27 | — | — | US | disclosed |
| US-20230091653-A1 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | SEAGEN INC. | 2023-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207427-A1 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | CTSB, CTSE, CTSZ | PRCP 20/4885MEN1 1450/4885KMT2A 3707/4885 |
| US-20240366779-A1 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | CTSB, CTSE, CTSZ | PRCP 20/4885MEN1 1450/4885KMT2A 3707/4885 |
| US-20250262312-A1 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | CTSB, CTSE, CTSZ | PRCP 20/4885MEN1 1450/4885KMT2A 3707/4885 |
| US-12036286-B2 | Selective drug release from internalized conjugates of biologically active compounds | CTSB, CTSE, CTSZ | PRCP 20/4885MEN1 1450/4885KMT2A 3707/4885 |
| US-20230091653-A1 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | CTSB, CTSE, CTSZ | PRCP 20/4885MEN1 1450/4885KMT2A 3707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.